Read it carefully and you'll find something remarkable — not alarm, not moral panic, but a measured, almost bored scientific assessment. Dr. W.W. Stockberger of the Bureau of Plant Industry told the publication there was "no reason to become excited about a sporadic outbreak of hasheesh addiction." Hemp had been growing wild across America for years. Workers labored in hemp fields their whole lives and "never became addicts." Cannabis had a "large and legitimate use in veterinary medicine." It grew wild from the Atlantic coast to the Western plains. It was, in the view of the government's own plant scientists, a weed.

There's a specific kind of credibility that only comes from the inside. When cannabis advocates say the Controlled Substances Act is a broken instrument of policy failure, it gets filed under "predictable." When a former senior DEA official writes the same thing in a peer-reviewed paper published in Science, it lands differently.

If you find this surprising, you haven't been paying close enough attention to what cannabis has always been in this country. It has never been about public health. It has never been about safety. It has been a political lever, pulled by whoever is in power, against whoever they need to target.

The United States Army just quietly removed one of its longest-standing barriers to enlistment. Recruits with a marijuana-related conviction were previously required to undergo a two-year waiting period, seek a special Pentagon waiver, and pass a drug test. Those restrictions have now been dropped for anyone with a single conviction for possessing marijuana or marijuana-related paraphernalia.

The growth medium is typically agar-based — yes, the same substance used in microbiology to grow bacterial cultures — infused with a formulation derived from something called Murashige and Skoog (MS) salts, a nutrient mixture developed in the 1960s that has become the foundation of plant tissue culture worldwide. To this base, you add specific plant hormones: cytokinins to promote shoot proliferation, auxins to promote rooting, and various other compounds depending on what growth stage you are trying to achieve.

So when the Lancet team searched databases for RCTs treating mental disorders with cannabis as the primary treatment, they found a sparse pool — and then concluded the sparse pool means cannabis doesn't work. That conclusion is circular. You can't run a rigorous trial with plant material you can barely access, in the doses people actually use, then fault the plant for the absence of results.

Nixon was a law-and-order president who weaponized federal agencies against political enemies, escalated a war he inherited, used moral panic to consolidate power, and ran a domestic drug policy built more on politics than pharmacology. He resigned in disgrace. Trump in his second term is operating in an eerily similar register. The rhetoric around drugs — fentanyl, the border, cartel activity — has been maximalist and deliberately inflammatory.

The New York Times flipped on cannabis last month. We covered that. Filed it, sourced it, called it what it was — institutional cowardice dressed as public health journalism. Then this week, the Wall Street Journal ran its version. AOL pushed its version. The same week. Different mastheads, same message.

The engine is Gen Z. Analytics firm Headset found that over the past year of national cannabis sales, Gen Z spent 38% of their dollars on vapor pens and only 32.5% on flower — the exact inverse of Millennials, who put 40% into flower and 25.7% into vapes. Gen Z is also the first cannabis-consuming generation to prefer the cart over everything else as their primary format.

What it became is one of the most consequential cannabis-related cases the Supreme Court has ever heard — sitting at the crossroads of the Second Amendment, federal drug law, and the legal fiction that cannabis users are inherently dangerous people who can't be trusted with firearms.